Peter Hammerman, M.D., Ph.D., is MOMA’s Chief Scientific Officer. He joined the company 2021 and is responsible for overseeing research activities spanning from target identification through translational studies.
A leading cancer biologist and oncologist, Peter joined MOMA from Novartis Institutes of Biomedical Research, where he served for nearly five years as global head of oncology translational research. At Novartis, Peter led a global team of 100 full-time employees focused on the discovery and development of novel cancer therapies, including small molecules, biologics and immunotherapeutics and was responsible for leading both laboratory research and analysis of specimens from Novartis clinical trials.
Previously, he spent more than eight years as a physician scientist at the Dana-Farber Cancer Institute, where he trained in medical oncology and then served as an assistant professor. While there, he led a translational research laboratory focused on experimental therapeutics, genomics and biomarker development in lung and head and neck cancers and was actively involved in clinical trials in these areas based on his laboratory research. Peter was a recipient of multiple grants from the federal government and private foundations and has published more than 100 peer reviewed manuscripts.
Before his time at Dana-Farber, Peter completed his internal medicine residency at Massachusetts General Hospital. Board certified in internal medicine and medical oncology, Peter holds a Ph.D. in cell and molecular biology from the University of Pennsylvania, an M.D. from the University of Pennsylvania School of Medicine and a Bachelor’s degree in biological sciences and history from Stanford University.